Cargando…
Long-term irreversible trastuzumab-induced cardiotoxicity for metastatic breast cancer in a patient without cardiac risk factors
Trastuzumab improves clinical outcomes in patients with human epidermal growth factor receptor-2-positive breast cancer. However, cardiotoxicity is a potentially important concern, and the long-term cardiac effects of trastuzumab therapy remain unclear. Although reduction of cardiac function by tras...
Autores principales: | Tanaka, Satoru, Ikari, Ayana, Nitta, Toshikatsu, Horiuchi, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499211/ https://www.ncbi.nlm.nih.gov/pubmed/28694974 http://dx.doi.org/10.1093/omcr/omx038 |
Ejemplares similares
-
Cardiotoxicity during long-term trastuzumab use in patients with HER2-positive metastatic breast cancer: who needs cardiac monitoring?
por: Bouwer, N. I., et al.
Publicado: (2021) -
Trastuzumab Cardiotoxicity in Patients with Breast Cancer
por: Freitas, Aguinaldo Figueiredo, et al.
Publicado: (2014) -
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
por: Ito, Mayuko, et al.
Publicado: (2021) -
Cardiotoxicity of concomitant radiotherapy and trastuzumab for early breast cancer
por: Marinko, Tanja, et al.
Publicado: (2014) -
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
por: Minichillo, Santino, et al.
Publicado: (2017)